Ultragenyx Pharmaceutical | RARE - Sales Revenues


Ultragenyx Pharmaceutical reported $207M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Acadia Pharmaceuticals USD 284M 5.4M Dec/2025
Agios Pharmaceuticals USD 19.97M 7.07M Dec/2025
Alnylam Pharmaceuticals USD 1.1B 150M Dec/2025
BioCryst Pharmaceuticals USD -86.95M 204.03M Dec/2024
BioMarin Pharmaceutical USD 875M 99M Dec/2025
Esperion Therapeutics USD 51.63M 22.2M Sep/2024
Insmed USD 263.8M 121.8M Dec/2025
Ionis Pharmaceuticals USD 203M 46M Dec/2025
Karyopharm Therapeutics USD 30.54M 8.24M Dec/2024
Kyowa Hakko Kirin JPY 147.38B 28.58B Dec/2025
MacroGenics USD 72.84M 50.6M Sep/2025
Moderna USD 678M 342M Dec/2025
Neurocrine Biosciences USD 805.5M 10.6M Dec/2025
PTC Therapeutics USD 164.7M 46.3M Dec/2025
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Sarepta Therapeutics USD 442.9M 43.5M Dec/2025
Ultragenyx Pharmaceutical USD 207M 47M Dec/2025
Vertex Pharmaceuticals USD 3.19B 110M Dec/2025
Xoma USD 25K 5M Sep/2024